Citius Pharmaceuticals Inc. (NASDAQ:CTXR) currently has a daily average trading volume of 1.40M but it saw 1213586 shares traded on Thursday. With a market cap of 164.29M USD, stock’s current market price of $1.08 came falling about -2.70 while comparing to the previous closing price of $1.11. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.71 and as low as $0.77. In the recent trading on the day, stock has struck highest price mark of $1.14 while lowest mark touched by it was $1.07.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Taking a look at 20-day trading activity of Citius Pharmaceuticals Inc. (CTXR) gives us an average price of $1.2660, while its current price level is -36.84% below from 52-week high level whereas it is 40.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2874 while that of 200 days or SMA-200 reads an average of $1.1878. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.30% during that period while stretching the period over a month that increases to 8.76%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 37.97 which implies that the stock is in neutral territory.
Citius Pharmaceuticals Inc. (CTXR)’s stock is currently under the radar of 3 analysts who are in consensus at a 12-month price target range of between $4.00 and $8.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $4.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $8.00. Average price target assigned by them is $6.00 which highlights an upside potential of 82.0% for the stock over that period. And to attain the median price target of $6.00 assigned by those analysts, stock has to add about 82.0% of value to its current levels.
Data by FactSet Research shows that 3 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 3 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.
Over the week, CTXR’s stock price is moving -4.42% down while it is -22.30% when we observe its performance for the past one month. Year-to-date it is 36.71% up and over the past year, the stock is showing an upside performance of 11.67%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.07 beaten by the consensus estimate of -$0.03 for the same. The company is expected to be releasing its next quarterly report in 08/10/2023, for which analysts forecasted an EPS of -$0.04 while estimate for next year EPS is -$0.15. For CTXR, analysts are forecasting an EPS-growth rate of 34.80% for current year and estimate for EPS growth in next year is 586.70%.
Currently, Citius Pharmaceuticals Inc.’s total number of outstanding shares is 146.25M with 8.42% of that held by the insiders while 11.48% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -30.70%. It has a 2.51 of forward P/E ratio. Stock’s beta reads 1.41. Stock has a price to book (P/B) ratio of 1.74. Its return on asset (ROA) is -27.50% on average.
Leave a Reply